Friday, May 24, 2019 - Activists have filed a class action lawsuit that alleges that certain drug companies that manufacture anti-HIV drugs such as Truvada, Descovy, Atripla, Genvoya, Odefsey, Viread, Emtriva, Complera, Stribild, Vemlidy, Reyataz, Evotaz, Prezista, Prezcobix, Edurant, Symtuza, and Tybost have conspired to monopolize the market for HIV prevention and treatment drugs and are taking advantage of people that are dying from HIV by charging exorbitant prices. According to PR Newswire.com, "the drug manufacturers used anti-competitive tactics to keep prices artificially high on some of the most important and widely used medicines for the treatment and prevention of the HIV virus, including Truvada."
Truvada lawsuit attorneys handling Truvada claims recommend a free consultation and no obligation before filing a lawsuit claim.
Drug companies are charging up to $35,000 per year for HIV positive patients in the United States to access the drug and the group of manufacturers has kept generic drugs from the US market. HIV treatment drugs are available in other countries that do not have "no generic drugs" laws such as Australia where HIV patients pay only $8 per daily dosage.
Daniel O'Day, the CEO of Gilead Sciences, the manufacturer and marketer of Truvada, was questioned before Congress the other day by freshman US Rep. Alexandria Ocasio-Cortez, D-N.Y who brought up the subject of why a company like Gilead that had revenues of over $3billion last year from sales of Truvada, could justify such obvious price gouging of people (HIV patients) that are desperate to save their own lives. Cortez claims that the patent for the drug is owned by the people, not Gilead, but the people have no way to enforce it. According to NBC News "There's no reason this (Truvada) should be (cost) $2,000 a month," said Ocasio-Cortez, who has pushed for the hearing before the House Committee on Oversight and Reform. "People are dying because of it, and there's no enforceable reason for it," said Cortez claiming that the US government was the one to discover Truvada. "Truvada use as an HIV prevention pill was discovered by the U.S. government," Cortez said.
Price gouging and market manipulation is only the tip of the iceberg regarding the problems surrounding Truvada. The active ingredient in Truvada, tenofovir disoproxil, has been shown to cause a loss of bone density called osteoporosis in HIV patients taking the drug. Bone density loss can lead to fractures mostly of the legs and hips. Truvada also leads to renal difficulties that can lead to kidney failure.
Gilead Sciences has been warned before by the US Food and Drug Administration (FDA) for making false safety claims about the drug. HIV patients that have taken Truvada and now suffer from osteoporosis are filing claims against Gilead for failing to warn them of the drug's potential adverse side effects. Plaintiffs also claim that had they know of the harm Truvada could cause they may have opted to take a different antiretroviral drug that may not carry the same risk for kidney and bone density problems.
OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The firm has represented thousands of persons in these and other products liability litigation, including DePuy hip replacement systems, which settled for $2.5 billion and Pradaxa internal bleeding, which settled for $650 million. The Onder Law Firm won over $300 million in four talcum powder ovarian cancer lawsuits in St. Louis to date and other law firms throughout the nation often seek its experience and expertise on complex litigation.